Search Results - "Jansat, J M"

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients by Joos, G.F, Schelfhout, V.J, Pauwels, R.A, Kanniess, F, Magnussen, H, Lamarca, R, Jansat, J.M, Garcia Gil, E

“…Summary Background Aclidinium bromide is a novel, long-acting, inhaled muscarinic antagonist bronchodilator currently in Phase III clinical development for the…”
Get full text

Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial by Piraccini, B.M., Blume‐Peytavi, U., Scarci, F., Jansat, J.M., Falqués, M., Otero, R., Tamarit, M.L., Galván, J., Tebbs, V., Massana, E.

“…Background Oral finasteride is a well‐established treatment for men with androgenetic alopecia (AGA), but long‐term therapy is not always acceptable to…”
Get full text

Pharmacokinetics and safety of oral almotriptan in healthy male volunteers by McEwen, J., Salva, M., Jansat, J.M., Cabarrocas, X.

“…Almotriptan (LAS 31416) is a new, oral, specific 5‐hydroxytryptamine1B/1D receptor agonist for the treatment of migraine. The pharmacokinetics and safety of a…”
Get full text

Effect of food intake on the bioavailability of almotriptan, an antimigraine compound, in healthy volunteers: an open, randomized, crossover, single-dose clinical trial by Jansat, J M, Martinez-Tobed, A, Garcia, E, Cabarrocas, X, Costa, J

“…This open, randomized, crossover, single-dose clinical trial evaluated the possible pharmacokinetic interaction between a single oral dose of almotriptan 25…”
Get full text

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers by Lasseter, K, Dilzer, S, Jansat, J.M, Garcia Gil, E, Caracta, C.F, Ortiz, S

“…Abstract Chronic obstructive pulmonary disease (COPD) is characterized by progressive airway obstruction and increased cholinergic tone. The Global Initiative…”
Get full text

Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects by Jansat, J M, Lamarca, R, Garcia Gil, E, Ferrer, P

“…Aclidinium bromide is a novel antimuscarinic being developed for the treatment of chronic obstructive pulmonary disease. The objective of this Phase I study…”
Get full text

Comparative study of different weighting methods in non-linear regression analysis: implications in the parametrization of carebastine after intravenous administration in healthy volunteers by Jansat, J M, Lastra, C F, Mariño, E L

“…The influence of different weighting methods in non-linear regression analysis was evaluated in the pharmacokinetics of carebastine after a single intravenous…”
Get more information

Parametrization by nonlinear regression analysis of the active acid metabolite of ebastine using different weighting methods by Mariño, E L, Jansat, J M, March, M A, Lastra, C F

“…The study of the analytical error function has been applied to evaluate the pharmacokinetics of ebastine active acid metabolite after a single oral dose of 10…”
Get more information

Disposition and metabolism of almotriptan in rats, dogs and monkeys by Aubets, J., Cardenas, A., Salva, M., Jansat, J. M., Martinez-Tobed, A., Palacios, J. M.

“…Almotriptan is a new highly potent selective 5-HT1B/1D receptor agonist developed for the treatment of migraine, and the disposition of almotriptan in…”
Get full text

Effect of MAO‐A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans by Fleishaker, Joseph C., Ryan, Kristi K., Jansat, Josep M., Carel, Barabara J., Bell, David J. A., Burke, Moira T., Azie, Nkechi E.

“…Aims  To assess the effect of a reversible MAO‐A inhibitor, moclobemide, on the single‐dose pharmacokinetics of almotriptan and assess the clinical…”
Get full text

Pharmacokinetic and pharmacodynamic studies of the histamine H1-receptor antagonist ebastine in dogs by Puigdemont, A, Queralt, M, Jansat, J M, Martinez-Tobed, A

“…The pharmacokinetics and pharmacodynamics of ebastine at single oral doses of 10 and 20 mg were studied in six healthy beagle dogs. Plasma concentrations of…”
Get more information

Identification of the Human Liver Enzymes Involved in the Metabolism of the Antimigraine Agent Almotriptan by SALVA, Miquel, JANSAT, Josep M, MARTINEZ-TOBED, Antonio, PALACIOS, Jose M

“…Almotriptan is a novel highly selective 5-hydroxytryptamine 1B/1D agonist developed for the acute oral treatment of migraine. The in vitro metabolism of…”
Get full text

Absolute Bioavailability, Pharmacokinetics, and Urinary Excretion of the Novel Antimigraine Agent Almotriptan in Healthy Male Volunteers by Jansat, Josep M., Costa, Joan, Salvà, Pau, Fernandez, Francisco J., Martinez-Tobed, Antonio

“…Absolute bioavailability, pharmacokinetics, and urinary excretion of almotriptan, a novel 5‐HT1B/1D receptor agonist, were studied in 18 healthy males…”
Get full text

Repeated dose pharmacokinetic study of the combination of ebastine and pseudoephedrine in healthy volunteers by JANSAT, J. M, ALVAREZ, P, HONORATO, J, LURIA, X, MARTINEZ-TOBED, A

Get full text

Almotriptan, a New Anti‐Migraine Agent: A Review by Gras, Jordi, Llenas, Jesús, Jansat, Josep M., Jáuregui, José, Cabarrocas, Xavier, Palacios, José M.

“…ABSTRACT Almotriptan is a new anti‐migraine agent with nanomolar affinity for human 5‐HT1B, 5‐HT1D, and 5‐HT1F receptors, weak affinity for 5‐HT1A and 5‐HT7…”
Get full text